Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 496 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9% Normal Saline (0.9% Sodium Chloride) injection Clear all
Completed Phase 4 Interventional Results available

Comparing Post-Op Narcotic Usage in Patients Receiving Periarticular Exparel vs. Standard Periarticular Joint Inj

NCT02682498
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee
Interventions
(Bupivacaine Liposome Injectable Suspension), Standard Preparation
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 15, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Ultrasound-guided Femoral Nerve Blocks in Elderly Patients With Hip Fractures

NCT01701414
View directory record Official record
Conditions
Femoral Neck Fractures, Hip Fractures
Interventions
Femoral nerve block: 25 mL of 0.5% bupivacaine, Placebo: 3cc of 0.9% Normal Saline
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
55 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 15, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia

NCT04652726
View directory record Official record
Conditions
Familial Hypercholesterolemia - Heterozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Tucson, Arizona • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 15, 2026, 1:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DMID 23-0015; Lassa Fever CVD 1000

NCT06546709
View directory record Official record
Conditions
Lassa Fever
Interventions
LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, Normal Saline Placebo, LASSARAB+ aPHAD-SEat 1400rU
Biological · Other
Lead sponsor
Wilbur Chen, MD, MS
Other
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 15, 2026, 1:43 PM EDT
Recruiting Phase 3 Interventional

Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt

NCT06938347
View directory record Official record
Conditions
Right-To-Left Shunt
Interventions
Agitated Saline SoC, ASI-02
Drug
Lead sponsor
Agitated Solutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Chicago, Illinois • Rochester, Minnesota • Saint Cloud, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 15, 2026, 1:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

NCT01264783
View directory record Official record
Conditions
Myocardial Infarct
Interventions
RNS60, Placebo
Drug
Lead sponsor
Revalesio Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 15, 2026, 1:43 PM EDT
Terminated Phase 1Phase 2 Interventional

Effect of Intravenous Lidocaine, Used to Attenuate Pain With Propofol Injection, on Defibrillation Threshold Testing

NCT03117166
View directory record Official record
Conditions
Pain
Interventions
lidocaine, Placebo
Drug
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 15, 2026, 1:43 PM EDT
Recruiting Early Phase 1 Interventional

TranExamic Atomized for Pediatric Post-Operative Tonsillectomy Hemorrhage: Pilot Study

NCT06580509
View directory record Official record
Conditions
Hemorrhage, Surgical, Tonsillar Bleeding
Interventions
Tranexamic Acid Injectable Product, Normal Saline
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
2 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 15, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Platelet-Rich Plasma (PRP) Injection for the Treatment of Chronic Patellar Tendinopathy

NCT01843504
View directory record Official record
Conditions
Chronic Patellar Tendinopathy, Chronic PT
Interventions
platelet rich plasma, saline
Biological · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 15, 2026, 1:43 PM EDT
Completed Phase 4 Interventional Results available

Study of EXPAREL in Patients Undergoing Breast Augmentation

NCT01582490
View directory record Official record
Conditions
Mammoplasty, Postoperative Pain
Interventions
Instillation - EXPAREL, Infiltration - EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 15, 2026, 1:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

NCT02325050
View directory record Official record
Conditions
Healthy
Interventions
MVA-BN-Filo, Ad26. ZEBOV, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 15, 2026, 1:43 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl

NCT06439992
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-Fluselenamyl
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 15, 2026, 1:43 PM EDT
Recruiting No phase listed Observational

Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.

NCT06252493
View directory record Official record
Conditions
Crohn Disease
Interventions
Radiotracer Injection, Contrast Media, Magnetic Resonance, Blood Draw, Glucagon, Imaging, Oral contrast media application
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 15, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional Results available

IL-1RA Treatment in Patients With Acute ACL Tear and Painful Effusions

NCT02930122
View directory record Official record
Conditions
Anterior Cruciate Ligament Tear
Interventions
anakinra (150mg), Saline intraarticularly
Drug · Other
Lead sponsor
Cale Jacobs, PhD
Other
Eligibility
14 Years to 40 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 15, 2026, 1:43 PM EDT
Recruiting Phase 4 Interventional

Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency

NCT06054880
View directory record Official record
Conditions
Ureter Injury
Interventions
Indigotindisulfonate sodium 0.8%, Saline injection 0.9%
Drug · Other
Lead sponsor
Prove pharm
Industry
Eligibility
18 Years to 85 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 15, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)

NCT03397121
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia, Elevated Cholesterol
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
Mission Viejo, California • Newport Beach, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 15, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

NCT00552058
View directory record Official record
Conditions
Crohn Disease
Interventions
certolizumab pegol (CDP870, CZP), Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
24
States / cities
Pell City, Alabama • Colorado Springs, Colorado • Lakewood, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 15, 2026, 1:43 PM EDT
Completed Phase 3 Interventional

Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

NCT04636229
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Amniotic Suspension Allograft, Placebo
Biological · Drug
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
38
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 15, 2026, 1:43 PM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

NCT07059091
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Allergies
Interventions
Omalizumab (Xolair®), Sodium Chloride (NaCl) 0.9 %
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 15, 2026, 1:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Combination of Magnesium and Lidocaine for the Pretreatment of Pain That is Caused by the Injection of Propofol

NCT01342510
View directory record Official record
Conditions
General Anesthesia, Intravenous Anesthesia
Interventions
Magnesium Sulfate, Lidocaine, Control, Lidocaine/Magnesium
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 15, 2026, 1:43 PM EDT
Completed Phase 2 Interventional

GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

NCT05189210
View directory record Official record
Conditions
Mild to Moderate Alzheimer's Disease
Interventions
GV1001 Placebo, GV1001 0.56mg, GV1001 1.12mg
Drug
Lead sponsor
GemVax & Kael
Industry
Eligibility
55 Years to 85 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Adventura, Florida • Greenacres City, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 15, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional

Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis

NCT05796765
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Micronized DHACM 40 mg, Micronized DHACM 100 mg, Saline
Biological · Drug
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
14
States / cities
La Mesa, California • Miami, Florida • The Villages, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 15, 2026, 1:43 PM EDT
Recruiting Phase 4 Interventional

The Effect of Local and Systemic Tranexamic Acid on Edema and Ecchymosis in Orbital Surgery

NCT06450392
View directory record Official record
Conditions
Orbital Edema, Orbital Ecchymosis
Interventions
Tranexamic acid injection, Tranexamic Acid in NaCl,Iso-Os 1,000 Mg/100 mL (10 Mg/mL) INTRAVEN INTRAVENOUS SOLUTION, PIGGYBACK (ML), normal saline - injection, normal saline - intravenous
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 15, 2026, 1:43 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease

NCT05731440
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-Fluselenamyl
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 15, 2026, 1:43 PM EDT